Quotient

Quotient Liabilities

Delisted

The The Liabilities of Quotient (QTNT) as of Nov 9, 2026 is 338.09 M USD. In the previous year, The Liabilities was 248.31 M USD — a change of 36.15% (higher).

Liabilities

338.09 MUSD

YoY

36.15%

Last updated:

In 2022, Quotient's total liabilities amounted to 338.09 M USD, a 36.15% difference from the 248.31 M USD total liabilities in the previous year.

The Quotient Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2015
82.73 M USD
Jan 1, 2016
73.03 M USD
Jan 1, 2017
134.06 M USD
Jan 1, 2018
138.47 M USD
Jan 1, 2019
176.06 M USD
Jan 1, 2020
231.99 M USD
Jan 1, 2021
248.31 M USD
Jan 1, 2022
338.09 M USD
The Quotient Liabilities history
YEARLiabilitiesYoY
338.09 MUSD+36.15%
248.31 MUSD+7.04%
231.99 MUSD+31.77%
176.06 MUSD+27.14%
138.47 MUSD+3.29%
134.06 MUSD+83.58%
73.03 MUSD-11.73%
82.73 MUSD+34.87%
61.34 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quotient Stock analysis

What does Quotient do? Quotient Ltd is a biopharmaceutical company headquartered in Eysins, Switzerland. The company was founded in 2007 with the aim of developing innovative technologies in the field of Personalized Medicine. This means that medications and therapies are specifically tailored to the individual needs of patients. Thanks to state-of-the-art production processes, products can be produced quickly and safely. Quotient Ltd has a unique business model based on transfusion technology. This technology allows the company to produce medications quickly and accurately. The different components of the medications are separated and then combined in the required dosage. This means that the medications can be precisely dosed and the risks of side effects minimized. A key focus of Quotient Ltd is the development of therapeutics. Personalized medicine and the fast and safe production of medications are at the center of this area. The transfusion technology enables medications to be produced quickly and flexibly, which is particularly important for rare diseases and personalized therapies. Another important area is the development of diagnostics. These enable diseases to be diagnosed quickly and safely. Based on this diagnosis, suitable therapies are then developed. Quotient Ltd also relies on transfusion technology for this, which enables fast, reliable, and flexible production of diagnostics. In addition to its developed technology and know-how, Quotient Ltd also has its own production facility. Here, all products are produced to the highest standards. The production facility covers an area of approximately 6,000 square meters. The modern facility is equipped with the latest technologies and meets the highest quality standards. Quotient Ltd offers a variety of products, with a special focus on personalized medicine and the fast and safe production of medications and diagnostics. One example is the PDA diagnostic system, which was developed for the fast and accurate diagnosis of autoimmune diseases. The MosaiQ system is another important product that enables fast and reliable production of medications. The success story of Quotient Ltd is closely linked to the development of transfusion technology. The company has succeeded in developing a technology that allows for the fast and safe production of personalized medicine. This technology has made Quotient Ltd a leading company in the field of personalized medicine worldwide. Today, Quotient Ltd employs over 700 people who are constantly working on the further development of personalized medicine and transfusion technology. Quotient is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Quotient's Liabilities

Quotient's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Quotient's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Quotient's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Quotient's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Quotient’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Quotient stock

The Liabilities of Quotient is 338.09 M USD in 2022.

The Liabilities of Quotient changed from 248.31 M USD to 338.09 M USD, representing a 36.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Quotient since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Quotient historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Quotient

All Key Metrics — Quotient